Colon cancer worse in African-Americans
Posted on: Monday, 19 January 2009, 22:43 CST
African-American colorectal cancer patients do worse than Caucasian ones, U.S. researchers found.
African-American patients are more likely to have worse pathological features at diagnosis and to have a worse five-year survival rate compared to Caucasian patients. Among patients diagnosed with early-stage disease, the risk for nodal involvement was also greater in African-American patients.
Right now, we cannot definitely explain why there are such differences between the African-American and the Caucasian patients,
study leader Dr. Edith Mitchell of Philadelphia's Thomas Jefferson University said in a statement.
Mitchell suggests one possible explanation is socioeconomic factors.
For example, research has shown that African-Americans are less likely than Caucasian patients to have health insurance, and thus they may not receive the screening necessary to detect colorectal cancer at an earlier stage,
Mitchell says in a statement.
The study is based on data from the tumor registry of Thomas Jefferson University Hospital on 2,500 colorectal cancer patients treated from 1988 to 2007, and on data from the National Cancer Institute's Surveillance, Epidemiology and End Results database on 244,701 colorectal cancer patients treated from 1988 to 2005.
The findings are being presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in Orlando, Fla.
Source: United Press International
Related Articles
- Cancer Patients Who Are Separated When Diagnosed Have Worse Survival Rates
- US Counties With More African-American Patients Could Have Fewer Colorectal Cancer Specialists
- '50 Nurses from 50 States' Visit Capitol Hill to Preserve Home Health Medicare Benefit for their Patients and All Americans
- Electronic Health Record Advances Patient-Centered Cancer Care
- Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
- FDA Approves FRAGMIN(R) As First Low-Molecular-Weight Heparin for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients With Cancer
- Cephalon Receives FDA Approval of FENTORA(TM) (Fentanyl Buccal Tablet) for the Management of Breakthrough Pain in Patients With Cancer
- Cephalon Receives Approvable Letter for FENTORA(TM) (Fentanyl Buccal Tablet) for Management of Breakthrough Pain in Patients With Cancer
- Randomized Trial Shows Ganite(R) Effective When Compared With a Leading Bisphosphonate in Patients With Cancer-Related Hypercalcemia
- Crohn's & Colitis Foundation of America Launches Education Campaign to Increase Awareness of Connection Between Inflammatory Bowel Disease and Colorectal Cancer During Colorectal Cancer Awareness Month
 |
 |
User Comments (0)
RSS Feeds